Seeing Is Believing
Currently out of the existing stock ratings of Andrew Peters, 33 are a BUY (97.06%), 1 are a HOLD (2.94%).
Analyst Andrew Peters, currently employed carries an average stock price target met ratio of 86.75% that have a potential upside of 59.27% achieved within 660 days. Previously, Andrew Peters worked at DEUTSCHE BANK, UBS.
Andrew Peters’s has documented 79 price targets and ratings displayed on 9 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on ESPR, Esperion Therapeutics at 03-May-2018.
Analyst best performing recommendations are on EXEL (EXELIXIS).
The best stock recommendation documented was for HALO (HALOZYME THERAPEUTICS) at 11/3/2016. The price target of $12 was fulfilled within 7 days with a profit of $3.54 (41.84%) receiving and performance score of 59.78.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
107
$15.79 (17.31%)
107
4 days ago
15/33 (45.45%)
$16.54 (18.28%)
454
Buy
115
$23.79 (26.08%)
112
10 days ago
5/11 (45.45%)
$22.43 (24.23%)
461
Buy
110
$18.79 (20.60%)
111
25 days ago
4/8 (50%)
$23.13 (26.63%)
266
Hold
100
$8.79 (9.64%)
100
25 days ago
1/7 (14.29%)
$13.13 (15.11%)
41
Hold
86
$-5.21 (-5.71%)
85
25 days ago
4/5 (80%)
$-0.87 (-1.00%)
74
What Year was the first public recommendation made by Andrew Peters?